2024 Volume 52 Issue 2 Pages 101-104
Objectives: Some patients report conductive hearing impairment during administration of clazosentan sodium. This study aimed to investigate the frequency of patients with fluid correction in their mastoid air cells.
Methods: We selected 25 consecutive patients with subarachnoid hemorrhage who were treated with clazosentan from January 2017 to January 2023. Fluid correction in their mastoid air cells was confirmed using computed tomography or magnetic resonance imaging.
Results: Fluid correction was observed in 19 of 25 cases. Two cases complained of conductive hearing loss. Each of these patients recovered their conductive hearing to within the normal range after clazosentan was discontinued.
Conclusion: Conductive hearing loss is a significant complication that physicians should be aware of, although this knowledge was not necessary to guide additional treatment.
